In most cancers, it interferes with protein targets of the phosphatidylinositol 3 kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) and mitogen-activated protein kinase (MAPK) signaling pathways [70]. This evidence concerns the gene AKT1 and cancer.